A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.

Yoko ChiharaMasafumi ShimodaAmi HoriAko OharaYasuto NaoiJun-Ichiro IkedaNaofumi KagaraTomonori TaneiAtsushi ShimomuraKenzo ShimazuSeung Jin KimShinzaburo Noguchi

Published in: Breast cancer research and treatment (2017)

This study indicates that the TGFβ-SMAD3 pathway plays an important role in the induction and maintenance of resistance to anti-HER2 drugs. Thus, SMAD3 is a potential therapeutic target that can inhibit resistance and restore sensitivity to anti-HER2 drugs.

Keyphrases

transforming growth factor
small molecule
epithelial mesenchymal transition
positive breast cancer
induced apoptosis
cell cycle arrest
cell proliferation
risk assessment
cell death
human health